Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase Ii clinical trial

Neychev, V.; Steinberg, S.M.; Cottle-Delisle, C.; Merkel, R.; Nilubol, N.; Yao, J.; Meltzer, P.; Pacak, K.; Marx, S.; Kebebew, E.

Bmj Open 5(5): E008248

2015

2044-6055

10.1136/bmjopen-2015-008248

https://eurekamag.com/research/058/366/058366307.php